Why Recursion Pharmaceuticals, Inc.’s (RXRX) Stock Is Down 9.28%
As of Thursday, November 05, Recursion Pharmaceuticals, Inc.’s RXRX share price has dipped by 9.28%, which has investors questioning if this is right time to buy.Jenna Brashear
Stock Evaluator: Recursion Pharmaceuticals, Inc. (RXRX)
Recursion Pharmaceuticals, Inc. RXRX
$3.55
0.05
1.29%
November 6, 2026 3:46:25 PM
EST
Volume: 12,144,067
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Commentary & Analysis
What You Need to Know About Recursion Pharmaceuticals, Inc.'s Q4 Earnings
Recursion Pharmaceuticals, Inc.'s fiscal Q4 earnings report was released on Monday, November 02. Let's dive in to see if (RXRX) missed or beat analyst's expectations.Rosalio Madrigal
Why Recursion Pharmaceuticals, Inc.’s (RXRX) Stock Is Down 8.02%
As of Friday, October 30, Recursion Pharmaceuticals, Inc.’s RXRX share price has dipped by 8.02%, which has investors questioning if this is right time to buy.Tudor Pop
Why Recursion Pharmaceuticals, Inc.’s (RXRX) Stock Is Up 6.67%
As of Wednesday, October 28, Recursion Pharmaceuticals, Inc.’s RXRX share price has surged by 6.67%, which has investors questioning if this is right time to sell.Jenna Brashear
Which Is a Better Investment, Recursion Pharmaceuticals, Inc. or Xencor, Inc. Stock?
Learn more about whether Recursion Pharmaceuticals, Inc. or Xencor, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Financial Summary
| Share Statistics | RXRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,178.7 | $214.3 | 56% |
|
| Shares Out (Mil) | 543.0 | 53.9 | 89% |
|
| Institutional Ownership | 95.8% | 92.9% | 68% |
|
| Float (Mil) | 607.4 | 41.4 | 87% |
|
| Beta | 1.15 | 0.96 | 68% |
|
| Avg Daily Volume (000s) | 22,004 | 506 | 98% |
|
| Price Change (52-week) |
(30.1%) | 43.9% | 29% |
|
| Growth | RXRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 79.6% | 13.2% | 98% |
|
| Net Income (5yr) | (49.3%) | (10.1%) | 7% |
|
| EPS (5yr) | 18.4% | 15.8% | 66 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (47.8%) | (15.7%) | 8% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 3 | 6 | |
| Current EPS | ($0.223) | ($0.893) | ($0.857) | |
| Month Ago EPS | ($0.226) | ($0.931) | ($0.902) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.222) | ($0.932) | ($0.911) | |
| Year/Year Chg | 1.8% | (38.0%) | (45.2%) | |
| Financials | RXRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $68 | $37 | 23% |
|
| Net Income (TTM) (Mil) | ($476) | ($44) | 3% |
|
| EPS (TTM) | ($0.895) | ($1.500) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | ($311) | ($34) | 3% |
|
| Net Cash Flow (TTM) (Mil) | ($106) | $1 | 14% |
|
| Long-Term Debt (Q1) (Mil) | $51 | $4 | 39% |
|
| Enterprise Value (Q1) (Mil) | $1,725 | $172 | 47% |
|
| Valuation | RXRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.17 | 2.00 | 58% |
|
| P/E | na | 18.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | RXRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (516.8%) | 67.3% | 0% |
|
| Net Margin | (697.1%) | (63.5%) | 1% |
|
| ROA | (36.3%) | (47.5%) | 15% |
|
| ROE | (48.7%) | (53.3%) | 15% |
|
| Liabilities to Assets | 25.9% | 29.6% | 18% |
|
| F-Score | 6 | 2 | 67% |
|
Recursion Pharmaceuticals, Inc. did not pass any screens on 11/5/2026.
